Orphan Designation for PBT434 for treatment of MSA
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Life Bioscience LLC leads strategic investment upto A$44.5M
- New data show potential for PBT434 to treat MSA
- Annual Report to shareholders
- Prana to present PBT434 data at International Congress
- First Volunteers Dosed in Phase I Clinical Trial of PBT434
Later from Alterity Therapeutics
- Prana receives A$3.3 million R&D Tax Incentive Refund
- Alterity presents initial Phase 1 clinical trial data at AAN
- Successful Completion of Phase 1 Clinical Trial
- Appendix 4E & Annual Report 2019
- Lead drug candidate receives positive opinion from EMA
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics